Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy

Annals of the Rheumatic Diseases

Volumn 73, Issue 5, 2014, Pages 909-912

  Das, Sudipto ^a,b   Vital, Edward M ^a,b   Horton, Sarah ^a,b   Bryer, Domini ^b   El Sherbiny, Yasser ^a,b,c   Rawstron, Andrew C ^b   Ponchel, Frederique ^a,b   Emery, Paul ^a,b   Buch, Maya H ^a,b  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; INTERLEUKIN 6; TOCILIZUMAB;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DAS28; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCARDITIS; ERYTHROCYTE SEDIMENTATION RATE; EXPLORATORY RESEARCH; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; LOWER RESPIRATORY TRACT INFECTION; LUPUS LIKE SYNDROME; LYMPHOCYTE DEPLETION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSORIASIS; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID LEVEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SYNOVIAL MEMBRANE; YOUNG ADULT;

EID: 84898016179     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204417     Document Type: Article

References (18)

1. National Institute of Health and Clinical Excellence. CG79 Rheumatoid Arthritis: the management of rheumatoid arthritis in adults. 2013 [cited 6 August 2013]; http://www.nice.org.uk/cg79
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care & Res 2012;64:625-39.
4. National Institute of Health and Clinical Excellence. Rheumatoid Arthritis - drugs for treatment after failure of a TNF inhibition (TA195). 2010 [cited 5 August 2013]; http://www.nice.org.uk/ta195
5. Bukhari M, Abernethy R, Deighton C, et al. BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 2011;50: 2311-3.
6. Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011;70:1575-80.
7. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Int Med 2006;144:865-76. (Pubitemid 46768126)
8. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Eng J Med 2005;353:1114-23. (Pubitemid 41317434)
9. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29. (Pubitemid 44497760)
10. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371: 987-97. (Pubitemid 351392039)
11. Smolen JS, Aletaha D, Redlich K. The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheum 2012;8:235-43.
12. Genovese MC, Breedveld FC, Emery P, et al. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:1894-7.
13. Mishra R, Singh V, Pritchard CH. Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatol Int 2011;31:481-4.
14. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010;62:1273-9.
15. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
16. Nishimoto N. Interleukin-6 in rheumatoid arthritis. Curr Opin Rheumatol 2006;18:277-81. (Pubitemid 43740380)
17. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8. (Pubitemid 32954353)
18. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 2009;68:1220-7